DelveInsight’s “Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hematopoietic Stem Cell Transplantation, historical and forecasted epidemiology as well as the Hematopoietic Stem Cell Transplantation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hematopoietic Stem Cell Transplantation market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Hematopoietic Stem Cell Transplantation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hematopoietic Stem Cell Transplantation Market Insights
Some of the key facts of the Hematopoietic Stem Cell Transplantation Market Report:
-
The Hematopoietic Stem Cell Transplantation market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
According to DelveInsight’s estimates, hematopoietic stem cell transplantation (HSCT) cases in the United States made up more than 40% of the total prevalent cases reported across the 7MM in 2023.
-
HSCT primarily consists of two types of transplants: autologous and allogeneic. According to DelveInsight’s consultant estimates, the majority of HSCT cases were autologous, accounting for approximately 60% of the cases in the United States in 2023.
-
Multiple myeloma/plasma cell disorders represent the largest prevalent patient population undergoing HSCT procedures across all the evaluated indications in the 7MM, except for Japan, where AML patients account for the majority of HSCT cases.
-
The United States accounts for about 65% of the hematopoietic stem cell transplantation market, exceeding the market sizes of the EU4, the UK, and Japan.
-
Iomab-B (I-131 apamistamab) is projected to achieve the largest market size among emerging therapies by 2034.
-
Key Hematopoietic Stem Cell Transplantation Companies: Sanofi, Actinium Pharmaceuticals, Medexus Pharmaceuticals /medac Pharma, Actinium Pharmaceuticals, BioLineRx, Medexus pharma, and others
-
Key Hematopoietic Stem Cell Transplantation Therapies: MOZOBIL (plerixafor), Iomab-B (CD45) (apamistamab-I-131), TRECONDI (treosulfan), Treosulfan, and others
-
The Hematopoietic Stem Cell Transplantation epidemiology based on gender analyzed that in the United States in 2021 was observed in patients with age 40 years and above, followed by 18-39 years and below 18 years
Hematopoietic Stem Cell Transplantation Overview
Hematopoietic stem cell transplantation (HSCT) administers healthy hematopoietic stem cells (HSC) to patients with defective or depleted bone marrow. This improves bone marrow function and, depending on the disease being treated, leads to either the destruction of malignant tumor cells or the generation of functional cells that can replace the dysfunctional ones, as in the case of immune-deficiency syndromes, hemoglobinopathies, and other diseases.
Get a Free sample for the Hematopoietic Stem Cell Transplantation Market Report:
https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-market
Hematopoietic Stem Cell Transplantation Market
The dynamics of the Hematopoietic Stem Cell Transplantation market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
“Recent advances in transplant immunology, supportive care and management of complications, and reduced toxicity conditioning have made Hematopoietic Stem Cell Transplantation an increasingly efficacious curative modality. More recently, immunotherapy is extending the curative potential of harnessing the immune system against cancer, to reduce the toxicities normally associated with conventional Hematopoietic Stem Cell Transplantation”
Hematopoietic Stem Cell Transplantation Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hematopoietic Stem Cell Transplantation Epidemiology Segmentation:
The Hematopoietic Stem Cell Transplantation market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Hematopoietic Stem Cell Transplantation
-
Prevalent Cases of Hematopoietic Stem Cell Transplantation by severity
-
Gender-specific Prevalence of Hematopoietic Stem Cell Transplantation
-
Diagnosed Cases of Episodic and Chronic Hematopoietic Stem Cell Transplantation
Download the report to understand which factors are driving Hematopoietic Stem Cell Transplantation epidemiology trends @ Hematopoietic Stem Cell Transplantation Epidemiological Insights
Hematopoietic Stem Cell Transplantation Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hematopoietic Stem Cell Transplantation market or expected to get launched during the study period. The analysis covers Hematopoietic Stem Cell Transplantation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hematopoietic Stem Cell Transplantation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hematopoietic Stem Cell Transplantation Therapies and Key Companies
-
MOZOBIL (plerixafor): Sanofi
-
Iomab-B (CD45) (apamistamab-I-131): Actinium Pharmaceuticals
-
TRECONDI (treosulfan): Medexus Pharmaceuticals /medac Pharma
-
Iomab-B: Actinium Pharmaceuticals
-
Motixafortide: BioLineRx
-
Treosulfan: Medexus pharma
To know more about Hematopoietic Stem Cell Transplantation treatment, visit @ Hematopoietic Stem Cell Transplantation Medications
Hematopoietic Stem Cell Transplantation Market Strengths
-
Hematopoietic Stem Cell Transplantation is the only potentially curative treatment for patients with chemotherapy-resistant hematological malignancies, which are usually fatal without treatment
-
Hematopoietic Stem Cell Transplantation is a widely accepted therapeutic modality for several malignant, hematologic, immunologic, and genetic diseases. This therapy consists of the intravenous infusion of hematopoietic progenitor cells to reestablish marrow function in patients with damaged or defective bone marrow
Hematopoietic Stem Cell Transplantation Market Barriers
-
Improved outcomes of Hematopoietic Stem Cell Transplantation are due to improvements in tissue typing, prophylaxis against viral and fungal infection, immunosuppressive drugs, and supportive care
-
Recognition of risk factors for complications allows the design of risk-specific supportive-care regimens that reduce the incidence of transplantation morbidity and mortality
Scope of the Hematopoietic Stem Cell Transplantation Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Hematopoietic Stem Cell Transplantation Companies: Sanofi, Actinium Pharmaceuticals, Medexus Pharmaceuticals /medac Pharma, Actinium Pharmaceuticals, BioLineRx, Medexus pharma, and others
-
Key Hematopoietic Stem Cell Transplantation Therapies: MOZOBIL (plerixafor), Iomab-B (CD45) (apamistamab-I-131), TRECONDI (treosulfan), Treosulfan, and others
-
Hematopoietic Stem Cell Transplantation Therapeutic Assessment: Hematopoietic Stem Cell Transplantation current marketed and Hematopoietic Stem Cell Transplantation emerging therapies
-
Hematopoietic Stem Cell Transplantation Market Dynamics: Hematopoietic Stem Cell Transplantation market drivers and Hematopoietic Stem Cell Transplantation market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Hematopoietic Stem Cell Transplantation Unmet Needs, KOL’s views, Analyst’s views, Hematopoietic Stem Cell Transplantation Market Access and Reimbursement
Discover more about therapies set to grab major Hematopoietic Stem Cell Transplantation market share @ Hematopoietic Stem Cell Transplantation market forecast
Table of Contents
1. Hematopoietic Stem Cell Transplantation Market Report Introduction
2. Executive Summary for Hematopoietic Stem Cell Transplantation
3. SWOT analysis of Hematopoietic Stem Cell Transplantation
4. Hematopoietic Stem Cell Transplantation Patient Share (%) Overview at a Glance
5. Hematopoietic Stem Cell Transplantation Market Overview at a Glance
6. Hematopoietic Stem Cell Transplantation Disease Background and Overview
7. Hematopoietic Stem Cell Transplantation Epidemiology and Patient Population
8. Country-Specific Patient Population of Hematopoietic Stem Cell Transplantation
9. Hematopoietic Stem Cell Transplantation Current Treatment and Medical Practices
10. Hematopoietic Stem Cell Transplantation Unmet Needs
11. Hematopoietic Stem Cell Transplantation Emerging Therapies
12. Hematopoietic Stem Cell Transplantation Market Outlook
13. Country-Wise Hematopoietic Stem Cell Transplantation Market Analysis (2020–2034)
14. Hematopoietic Stem Cell Transplantation Market Access and Reimbursement of Therapies
15. Hematopoietic Stem Cell Transplantation Market Drivers
16. Hematopoietic Stem Cell Transplantation Market Barriers
17. Hematopoietic Stem Cell Transplantation Appendix
18. Hematopoietic Stem Cell Transplantation Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/